Open Access Research article

Transcriptomic signature of Bexarotene (Rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models

Martin C Abba14, Yuhui Hu1, Carla C Levy1, Sally Gaddis1, Frances S Kittrell2, Yun Zhang2, Jamal Hill2, Reid P Bissonnette3, Daniel Medina2, Powel H Brown2 and C Marcelo Aldaz1*

Author Affiliations

1 Department of Carcinogenesis, The University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, 78957, TX, USA

2 Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, 77030, TX, USA

3 Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, California, 92121, USA

4 CINIBA, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina

For all author emails, please log on.

BMC Medical Genomics 2008, 1:40  doi:10.1186/1755-8794-1-40

Published: 11 September 2008

Additional files

Additional file 1:

Differentially expressed genes in mammary gland as the result of systemic bexarotene treatment versus control. The data provided represent the statistical analysis of SAGE libraries from p53-Null, MMTV-erbB2 and C3(1)/SV40 transgenic mice mammary cancer models (p < 0.05).

Format: XLS Size: 361KB Download file

This file can be viewed with: Microsoft Excel Viewer

Open Data

Additional file 2:

Co-occurring mammary gland deregulated transcripts as the result of systemic bexarotene treatment among transgenics mice mammary cancer models. The data provided represent the inter-model comparison for the identification of overlapping gene expression profiles among transgenics mice mammary cancer models (p < 0.05).

Format: XLS Size: 55KB Download file

This file can be viewed with: Microsoft Excel Viewer

Open Data